Article

Punctal plugs plus topical agent maximize eye relief

Fort Lauderdale, FL—A dual treatment approach combining punctal plugs with use of topical cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) affords dry eye sufferers greater improvement in their signs and symptoms than monotherapy with either modality alone, said Calvin W. Roberts, MD.

Dr. Roberts, clinical professor of ophthalmology, Weill Medical College of Cornell University, New York, reported the results of a parallel comparison study in which 30 consecutive patients with bilateral dry eye symptoms and 2+ conjunctival staining with lissamine green were randomly assigned to receive topical cyclosporine twice a day, punctal plugs to the lower lids only, or combination treatment. Responses were evaluated after 1, 3, and 6 months by assessing Schirmer test results (5 minutes with anesthesia), conjunctival staining scores, and frequency of use of artificial tears for symptom relief. He presented the results at the Association for Research in Vision and Ophthalmology annual meeting here earlier this month.

After just 1 month, punctal plugs were associated with marked improvement in Schirmer scores and decreased frequency of artificial tear use, but that intervention had little effect on conjunctival staining. Onset to efficacy took longer with cyclosporine monotherapy, but all three measures of efficacy eventually improved with its use. However, patients in the combination group enjoyed the benefits of both modalities with improvements that occurred early and that were equal or superior to those associated with either of the monotherapies.

Mean lissamine green conjunctival staining scores in the three groups ranged from 2 to 2.3 at baseline (possible score range, 0 to 4). All groups showed a modest benefit after 1 month (mean change range, –0.2 to –0.3), and there was no further improvement throughout the course of the study in the patients using punctal plugs. However, patients using cyclosporine alone or in combination with punctal plugs achieved greater reductions in conjunctival staining after 3 months and further benefit by study conclusion when mean changes from baseline were –0.9 and –1, respectively.

Mean frequency of artificial tear instillation at baseline ranged from 5.5 to 6.0 times daily across the three treatment groups. By 1 month, patients who had punctal plugs placed reduced their usage by about two instillations a day whether or not they also were using cyclosporine whereas patients using cyclosporine monotherapy had minimal change (–0.6).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.